Maternal corticosteroid use and fetal growth: risk-benefit analysis

Antenatal corticosteroids are among the most important interventions for pregnancies at risk of preterm birth. Betamethasone and dexamethasone accelerate fetal lung maturation and reduce respiratory distress, intraventricular hemorrhage, and neonatal death in appropriately selected pregnancies. Their use, however, requires more than a simple calculation based on gestational age. The likely effects on fetal growth, glucose regulation, infection risk, and long-term development also deserve attention.

Fetal growth restriction adds complexity to this decision. A fetus that is small for gestational age may have limited placental reserve, altered blood flow, or chronic exposure to an adverse intrauterine environment. Clinicians must weigh the immediate advantages of corticosteroid exposure against uncertainty about how the treatment may influence growth, birth weight, and later health.

This subject has particular relevance to perinatal teams working across different health systems and resource settings. The scientific discussions associated with the FAOPS 2020 congress reflected the continuing importance of coordinated research in perinatal and neonatal medicine, especially when treatment decisions involve competing short- and long-term outcomes.

Why timing matters in antenatal corticosteroid therapy

The principal benefit of antenatal corticosteroids occurs when preterm birth is likely within approximately seven days. Corticosteroids stimulate surfactant production, improve lung compliance, and support maturation of several organ systems. The strongest evidence traditionally concerns pregnancies at risk of delivery between 24 and 34 weeks, although many guidelines now support selected use in the late-preterm period after individualized assessment.

The timing of exposure matters because fetal development continues rapidly during the late second and third trimesters. A single course given shortly before a medically indicated preterm birth is different from repeated courses administered weeks apart, or from exposure when delivery is unlikely. A course given too early may offer little neonatal benefit by the time birth occurs, while unnecessary repeat exposure may increase concern about fetal growth and metabolic effects.

The clinical question is therefore not whether corticosteroids can affect fetal biology. They can. The more useful question is whether the expected neonatal benefit exceeds the possible harms for this pregnancy, at this gestational age, with this degree of delivery risk.

Fetal growth restriction changes the balance

Fetal growth restriction is usually defined through estimated fetal weight, abdominal circumference, growth velocity, Doppler findings, and the clinical context. Small size alone does not always indicate pathological restriction. A constitutionally small fetus with normal placental function may face a different risk profile from a fetus with absent end-diastolic flow, oligohydramnios, maternal hypertension, or deteriorating biophysical findings.

Studies of antenatal corticosteroids and fetal growth have produced mixed results. A single recommended course may be associated with a modest reduction in birth weight or fetal growth velocity in some populations, but the effect is difficult to separate from the underlying reason for preterm birth. Placental insufficiency, preeclampsia, infection, multiple gestation, and fetal anomalies can all influence growth and neonatal outcomes independently of steroid treatment.

Repeated courses raise greater concern. Some research has linked multiple exposures with lower birth weight or smaller head circumference, although findings vary according to dose, interval, gestational age, and population. For this reason, repeat therapy is generally reserved for situations in which the risk of preterm birth remains high and enough time has passed since the initial course. Routine weekly courses are not supported by the balance of evidence.

Interpreting evidence across gestational ages

At very early gestational ages, the absolute risk of respiratory morbidity and death is high. If delivery appears imminent, the potential value of corticosteroids is substantial, including for growth-restricted fetuses. The presence of FGR should not automatically exclude treatment when the neonatal team believes that birth is likely within the evidence-supported window.

Between 28 and 34 weeks, the benefit-risk balance is often clearest. A first course can reduce serious respiratory complications, while the incremental effect on fetal growth is usually smaller than the consequences of severe prematurity. Still, clinicians should consider whether labor is established, membranes are ruptured, infection is suspected, or delivery is being planned because of maternal or fetal deterioration.

In the late-preterm period, decisions become more selective. The risk of respiratory distress is lower than at earlier gestations, and the possibility of neonatal hypoglycemia becomes more prominent. This is particularly relevant when fetal growth restriction, maternal diabetes, or placental disease is present. The treatment decision should incorporate local neonatal capacity, expected birth timing, fetal surveillance, and the likelihood that delivery will actually occur soon.

Maternal and neonatal effects require monitoring

Corticosteroids can raise maternal blood glucose, sometimes substantially. This is important for people with pregestational or gestational diabetes, but transient hyperglycemia can also occur in those without known diabetes. Antenatal teams may need to increase glucose surveillance and adjust insulin or other treatment according to local protocols. Poor glycemic control can itself affect neonatal adaptation and complicate interpretation of newborn glucose measurements.

Neonatal hypoglycemia is a recognized concern, particularly after late-preterm corticosteroid exposure. The risk does not negate the respiratory benefits in every case, but it means that birth should occur in a setting capable of early feeding support and glucose monitoring. Growth-restricted infants already have reduced glycogen stores and may be more vulnerable to low glucose, temperature instability, and feeding difficulties.

Infection risk should also be considered. Corticosteroids can modify immune and inflammatory responses, while conditions such as chorioamnionitis, prolonged rupture of membranes, and maternal fever may independently increase neonatal infection risk. Steroids should not delay indicated delivery or antibiotic treatment. They are part of an integrated plan, not a substitute for managing the underlying obstetric problem.

Long-term outcomes and shared decisions

Short-term neonatal survival is only one endpoint. Families and clinicians also care about cognition, motor development, behavior, school performance, respiratory health, and quality of life. Available follow-up studies generally provide reassurance that a clinically indicated single course does not produce a clear pattern of major long-term neurodevelopmental harm. Yet long-term evidence is less complete for repeated courses, very late exposure, and infants with severe growth restriction.

Interpretation is complicated by confounding. The pregnancies receiving corticosteroids are often those already at high risk because of placental insufficiency, hypertension, inflammation, or threatened early delivery. These conditions can affect development independently. Researchers must therefore separate treatment effects from the biological consequences of prematurity and fetal disease.

For families seeking more context about outcomes after early birth, this discussion of long-term neurodevelopmental outcomes offers a useful reminder that follow-up should extend beyond discharge. Shared decision-making should explain the likely benefit, the uncertainties, and the monitoring plan in clear language rather than presenting corticosteroids as either universally safe or inherently harmful.

Applying the evidence at the bedside

A practical assessment begins with the probability and timing of birth. The team should review cervical change, labor progression, membrane status, bleeding, infection, maternal disease, fetal monitoring, Doppler results, and any planned delivery for fetal or maternal indications. When birth is unlikely within the relevant window, delaying treatment may avoid unnecessary exposure without compromising neonatal benefit.

Growth assessment should be interpreted dynamically. A single estimated fetal weight does not show whether the fetus is maintaining its growth trajectory. Serial biometry, umbilical artery Doppler, middle cerebral artery findings where appropriate, amniotic fluid volume, and maternal symptoms can provide a more reliable picture of placental function. Delivery planning should reflect the whole pattern rather than a percentile in isolation.

Useful safeguards include:

• Confirm that preterm birth is sufficiently likely before giving a course.
• Distinguish isolated small size from true fetal growth restriction and placental insufficiency.
• Use a single course when indicated, avoiding routine or automatic repeat treatment.
• Prepare for maternal hyperglycemia and neonatal hypoglycemia, especially with diabetes or FGR.
• Document gestational age, drug, dose, timing, delivery probability, and the reason for treatment.

The final decision should be made by an appropriately trained obstetric and neonatal team, with the pregnant patient included wherever circumstances permit. Local guidelines may differ in gestational-age thresholds, repeat-course criteria, and late-preterm practice because recommendations evolve as new evidence emerges. The central principle remains consistent: maximize the chance of meaningful neonatal benefit while limiting exposure that has little expected value.

Perinatal services can strengthen this process by combining antenatal counseling, fetal surveillance, neonatal preparation, and structured developmental follow-up. Reviewing outcomes across hospitals and populations will help clarify how corticosteroids interact with placental disease, fetal growth restriction, diabetes, and prematurity. Clinicians and researchers should continue contributing high-quality data so that future recommendations become more precise for the infants and families most likely to benefit.